Clinical Trial

NeurAxis Announces New Submission to the FDA for the Expansion of its IB-Stim Label; Provides Compliance with NYSE Guidelines on Audit Disclosure

CARMEL, Ind., June 07, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology…

2 months ago

Article in Nature Scientific Reports Describes Mechanism of Action of SeaStar Medical’s Selective Cytopheretic Device in the Immunomodulation of Excessive Inflammation

DENVER, June 07, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary…

2 months ago

Zeta Surgical’s AI-Powered Navigation System Successfully Completes First Clinical Study

SINGAPORE, June 7, 2024 /PRNewswire/ -- Zeta Surgical, a surgical robotics and mixed reality company, announced today the completion of its…

2 months ago

AI Based Wound Care Software Market to Record an Exponential CAGR by 2031 – Exclusive Report by InsightAce Analytic

JERSEY CITY, N.J., June 6, 2024 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report…

2 months ago

Health Catalyst Acquires Oncology-Focused Health Technology Company Carevive

SALT LAKE CITY, June 6, 2024 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and…

2 months ago

Tigermed Advances Clinical Data Management with Veeva Vault EDC

Modern EDC streamlines key processes to accelerate study builds and make mid-study amendments with no downtime PLEASANTON, Calif., June 6,…

2 months ago

How Merck Scientists Are Driving Next-Generation Cancer Research

The company's scientists are accelerating research by looking to improve anti-tumor immune response, targeting specific cancer cells and helping inhibit…

2 months ago

FDA Accepts for Review Treosulfan NDA Resubmission

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 6, 2024) - On Thursday, June 6, 2024, Medexus Pharmaceuticals (TSX: MDP)…

2 months ago

Moderna’s Investigational Therapeutic for Methylmalonic Acidemia (mRNA-3705) Selected by U.S. Food & Drug Administration for START Pilot Program

Center for Biologics Evaluation and Research has chosen mRNA-3705 as one of four investigational medicines for accelerated development to address…

2 months ago

Zomedica Announces Presentation of Compelling TRUFORMA(R) Research Findings and Educational Programs at Major Veterinary Internal Medicine Conference

New research data confirms superiority of TRUFORMA's Bulk Acoustic Wave Sensor technology in diagnosing feline hyperthyroidism ANN ARBOR, MI /…

2 months ago